The Pharmacist

DECEMBER 18, 2024

Four in 10 pharmacy owners are worried that their business may not survive the winter, recent polling by Community Pharmacy England (CPE) suggests. Some 39% of contractors said they were 'very concerned' about their pharmacy business going into winter, warning that they were worried about having to close permanently. Meanwhile, 81% warned of longer waiting […] The post Four in ten contractors warn their pharmacy may not survive the winter appeared first on The Pharmacist.

Community Pharmacies 69

Community Pharmacies 69

STAT

DECEMBER 20, 2024

Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future competitiveness of the company in the booming weight loss market. The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at all participants, including those who dropped out, Novo said Friday.

Drug Development 259

Drug Development 259

PharmaVoice

DECEMBER 20, 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

147

147

ALiEM - Pharm Pearls

DECEMBER 20, 2024

A 3-year-old male with a history of severe atopic dermatitis presented for facial rash and hand pain. Mom had been applying Aquaphor and Vaseline several times a day. On the day of presentation, he woke up with a new rash over his face and hands which prompted the ED visit. He is up to date on childhood immunizations and is not prescribed any oral medications.

Immunity 130

Immunity Immunization 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

Express Pharma

DECEMBER 20, 2024

Indias life sciences industry continues to demonstrate its stature as a global powerhouse, often referred to as the pharmacy of the world. Renowned for its extensive production of generic drugs and vaccines, the sector has played a pivotal role in addressing global healthcare demands. As of 2024, India has produced nearly half of the eight billion vaccine doses distributed worldwide, cementing its reputation as a reliable healthcare contributor.

Biosimilars 101

Biosimilars Vaccines 101

STAT

DECEMBER 20, 2024

The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S. Zepbound, whose scientific name is tirzepatide, has now been specifically approved for patients with both obesity and moderate-to-severe obstructive sleep apnea, or OSA, a condition characterized by breathing interruptions during sleep.

283

283

pharmaphorum

DECEMBER 19, 2024

At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.

96

96

Express Pharma

DECEMBER 20, 2024

AbbVie recently announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinsons disease (PD). Tavapadon, the first and only D1/D5 partial agonist in the dopamine agonist class, is under investigation as a once-daily treatment for PD. The trial met both its primary and secondary endpoints, suggesting that tavapadon has the potential to become a prominent treatment within the dopamine agonist market

97

97

STAT

DECEMBER 19, 2024

The Food and Drug Administration on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will soon put a stop to companies making cheaper copies of the injection. The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.

Compounding 232

Compounding Compounding Pharmacies Diabetes 232

PharmaVoice

DECEMBER 19, 2024

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.

130

130

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

The Pharmacist

DECEMBER 16, 2024

The eligible patient cohorts for vaccination under the spring 2025 Covid-19 programme have been confirmed, following recommendations from government advisors. In a letter sent to community pharmacies and others, NHS England announced the spring programme will cover: adults aged 75 years and over; residents in care homes for older adults; and individuals aged six months […] The post Government confirms Covid vaccine eligibility for spring 2025 programme appeared first on The Pharmacist.

Vaccines 98

Vaccines Community Pharmacies 98

Express Pharma

DECEMBER 15, 2024

The All India Pharmaceutical Associations Consortium (AIPAC) launched its first programme for Micro, Small, and Medium Enterprises (MSMEs) in the pharmaceutical sector on 12 December 2024. The event took place at the Prestige Institute of Management & Research, Indore, and was inaugurated by Dr Rajeev Singh Raghuvanshi, the Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO).

Pharmaceutical Manufacturing 102

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 102

STAT

DECEMBER 18, 2024

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

246

246

PharmaVoice

DECEMBER 18, 2024

The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.

130

130

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

The Pharmacist

DECEMBER 19, 2024

The drug atomoxetine and stimulants are the most effective treatments for adults with attention deficit hyperactivity disorder (ADHD), a new study has found. Researchers said their landmark systematic review, which included over 14,800 participants, sets a new benchmark for treatment of ADHD, and should inform future guidelines. However, they noted that the studys applicability to […] The post Atomoxetine and stimulants best treatments for adult ADHD, study suggests appeared first on The P

93

93

Express Pharma

DECEMBER 18, 2024

South Korea has emerged as a global leader in the biopharmaceutical industry, driven by its advanced clinical research infrastructure and government support. Key companies like Celltrion and Samsung Bioepis dominate the biosimilars market, contributing significantly to the approvals and pipelines. Celltrions strong presence in deal-making further underscores South Koreas growing influence in the global biosimilars landscape, reveals GlobalData.

Biosimilars 94

Biosimilars 94

STAT

DECEMBER 19, 2024

Most of the formularies run by some of the largest health plans in the U.S. generally provide “fair access” to 11 treatments for several serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis has found. Almost uniformly, the 11 formularies made the drugs available fairly when judged on three criteria: eligibility based on clinical data, restrictions placed on prescribers, and step therapy, which requires patients to try other

Department of Veterans Affairs 226

Department of Veterans Affairs Diabetes Drug Pricing 226

PharmaVoice

DECEMBER 17, 2024

Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Pharmacist

DECEMBER 17, 2024

Around half of adults in the UK struggle to access trusted health information, according to a new report. The study, published by the Patient Information Forum (PIF) and Ipsos,called Knowledge is Power, found that 53% of people felt they could trust the health information they found offline, with 45% saying they could trust the information […] The post Half of adults struggle to access trusted health information appeared first on The Pharmacist.

88

88

Express Pharma

DECEMBER 18, 2024

Mesoblast recently announced positive Phase III trial results in the European Journal of heart failure. The use of Revascor (rexlemestrocel-L) improved survival and reduced major morbidity in high-risk patients with ischemic heart failure (HF) and inflammation. This study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which highlights that Mesoblast holds potential to differentiate in HF, says GlobalData.

Hospitals 93

Hospitals Diabetes 93

STAT

DECEMBER 14, 2024

Novo Holdings, the parent company of Novo Nordisk, can proceed with its planned $16.5 billion acquisition of Catalent, a leading contract drug manufacturer, after U.S. regulators declined to challenge the deal following months of scrutiny. The companies expect to close the transaction in the next several days, after a deadline passed for the U.S. Federal Trade Commission to raise objections and other regulatory conditions were fulfilled, according to statements issued by Novo Nordisk and Catalen

Drug Pricing 238

Drug Pricing 238

PharmaVoice

DECEMBER 17, 2024

Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.

130

130

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

BioPharma Dive

DECEMBER 17, 2024

Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.

93

93

Express Pharma

DECEMBER 16, 2024

On December 13, 2024, Lupin, a global pharmaceutical company, announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH. The move is aimed at strengthening Lupins diabetes portfolio in India. The trademark rights for these brands are set to be transferred to Lupin by March 2025.

Diabetes 98

Diabetes Pharmaceutical Companies Pharmaceutical Companies 98

STAT

DECEMBER 18, 2024

James Mannion knew what he needed. For nine months, while incarcerated in a county jail in Portland, Maine, he pleaded for a medication called buprenorphine. Mannion, a barber, recreational fisherman, and father of two, was once a regular heroin user, but had used the medication to eliminate the cravings and withdrawal he experienced whenever he tried to quit opioids cold turkey.

195

195

PharmaVoice

DECEMBER 16, 2024

How recent setbacks and scattered successes could impact various sectors of the industry.

130

130

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

DECEMBER 18, 2024

The FDA has started a review of MSD's RSV antibody clesrovimab, a potential rival to Beyfortus, with a verdict due in the middle of next year

89

89

Express Pharma

DECEMBER 19, 2024

Lonza, a global manufacturing partner for the pharmaceutical, biotech, and nutraceutical sectors, has announced capacity expansions at its facilities in Rewari, India, and Suzhou, China. The expansion includes additional hard gelatin capsule (HGC) production lines to support the manufacture of high-quality capsules for the pharmaceutical and nutraceutical industries.

Dosage 84

Dosage 84

STAT

DECEMBER 20, 2024

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we do foresee a few developments, such as promenading the official mascots, hanging with one of our short people, and escorting Mrs. Pharmalot to a house party or two.

Compounding 170

Compounding Diabetes 170

PharmaVoice

DECEMBER 16, 2024

With a little more certainty coming to the market, the R&D environment in 2025 will be about pipeline prioritization and accelerating M&A.

100

100

pharmaphorum

DECEMBER 19, 2024

Novo Holdings' $16.

83

83